New hope for rare blood cancer: phase 3 trial of XNW5004 launches

NCT ID NCT06776952

Recruiting now Disease control Sponsor: Evopoint Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if XNW5004 delays cancer progression better than chidamide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XNW5004
What this could lead to: If it works, this could provide a new treatment option for people with relapsed or refractory peripheral T-cell lymphoma, potentially slowing disease progression.
What could go wrong: This is an early-stage Phase 3 trial with only 120 participants, so results may not apply to everyone. The drug may not be more effective than existing treatments and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Beijing Friendship Hospital,Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.